Suzetrigine for Postoperative Pain
(SUSI Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
The goal of this clinical trial is to determine whether suzetrigine, when added to standardized multimodal postoperative analgesia improves pain control and reduces opioid consumption after apical suspension surgery for pelvic organ prolapse.
Researchers will compare suzetrigine to a placebo (a look-alike substance that contains no drug) to evaluate this outcome.
The main questions it aims to answer are:
* Does suzetrigine reduce postoperative pain scores compared to placebo?
* Does suzetrigine reduce the need for opioid rescue medication after surgery?
Researchers will compare participants receiving suzetrigine to participants receiving placebo, both on top of standard postoperative pain management, to see if suzetrigine lowers pain scores and opioid consumption after apical suspension surgery.
Who Is on the Research Team?
Amanda White, MD
Principal Investigator
University of Texas at Austin Dell Medical School, Department of Women's Health
Are You a Good Fit for This Trial?
This trial is for adults having apical suspension surgery to treat pelvic organ prolapse. Participants must be able to follow study instructions and receive standard pain management after surgery.Inclusion Criteria
Exclusion Criteria
What Are the Treatments Tested in This Trial?
Interventions
- Suzetrigine
Trial Overview
The study tests whether adding suzetrigine to usual pain medications helps control pain and reduces the need for opioids after pelvic organ prolapse surgery, compared to a placebo. Participants are randomly assigned to either group.
How Is the Trial Designed?
2
Treatment groups
Experimental Treatment
Participants will receive suzetrigine 100 mg (2 tablets) as a loading dose on the evening of surgery, followed by 50 mg every 12 hours for 7 days, in addition to standard multimodal analgesia. Standard analgesia consists of ibuprofen 600 mg every 6 hours and acetaminophen 650 mg every 6 hours, scheduled for the first 48 hours postoperatively, after which patients may transition to as-needed dosing of both. An opioid prescription will be sent if triggered by previously set score and based on the patient's reported pain score.
Participants will receive matching placebo as a loading dose (2 tablets) on the evening of surgery, followed by 1 tablet every 12 hours for 7 days, in addition to standard multimodal analgesia. Standard analgesia consists of ibuprofen 600 mg every 6 hours and acetaminophen 650 mg every 6 hours, scheduled for the first 48 hours postoperatively, after which patients may transition to as-needed dosing of both. An opioid prescription will be sent if triggered by the patient's reported pain score.
Find a Clinic Near You
Who Is Running the Clinical Trial?
Aditi Talkad
Lead Sponsor
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.